Posted by Michael Wonder on 17 Jan 2019
Acurx receives FDA fast track designation for ACX-362E for the treatment of C. difficile infection
16 January 2019 - Phase 1 clinical study underway - anticipated completion second quarter 2019.
Acurx Pharmaceuticals announced today that the U.S. FDA has granted fast track designation for ACX-362E, an investigational new treatment for Clostridium difficile Infection. ACX-362E is a novel, oral antibiotic that recently entered Phase 1 development.
ACX-362E is a novel, first-in-class, orally-administered anti-bacterial. It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
